These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26695682)

  • 21. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
    Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
    Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA.
    Kiri VA; Bettoncelli G; Testi R; Viegi G
    Respir Med; 2005 Sep; 99(9):1115-24. PubMed ID: 15921904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease.
    Gershon AS; Campitelli MA; Croxford R; Stanbrook MB; To T; Upshur R; Stephenson AL; Stukel TA
    JAMA; 2014 Sep; 312(11):1114-21. PubMed ID: 25226477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonologists Adherence to the Chronic Obstructive Pulmonary Disease GOLD Guidelines: A Goal to Improve.
    Rajnoveanu RM; Rajnoveanu AG; Ardelean AB; Todea DA; Pop CM; Antoniu SA; Motoc NS; Chis AF; Fildan AP; Man MA
    Medicina (Kaunas); 2020 Aug; 56(9):. PubMed ID: 32825456
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
    Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
    Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
    Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
    COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhaled corticosteroids in COPD: a controversy.
    Barnes PJ
    Respiration; 2010; 80(2):89-95. PubMed ID: 20501985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis.
    Penning-van Beest F; van Herk-Sukel M; Gale R; Lammers JW; Herings R
    Respir Med; 2011 Feb; 105(2):259-65. PubMed ID: 20705441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 - 2010).
    Prat M; Gavaldà A; Fonquerna S; Miralpeix M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1543-73. PubMed ID: 21702714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    Sin DD; Man SF
    Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).
    Cecere LM; Slatore CG; Uman JE; Evans LE; Udris EM; Bryson CL; Au DH
    COPD; 2012 Jun; 9(3):251-8. PubMed ID: 22497533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
    Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
    Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies.
    Fitzgerald MF; Fox JC
    Drug Discov Today; 2007 Jun; 12(11-12):472-8. PubMed ID: 17532532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease": a consensus document.
    Alcázar Navarrete B; Casanova C; Miravitlles M; de Lucas P; Riesco JA; Rodríguez González-Moro JM;
    Arch Bronconeumol; 2015 Apr; 51(4):193-8. PubMed ID: 25540900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
    Kelly E
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.